Attachment of [35S]cysteine to the labile site of the third component of complement via the alternative pathway

Cynthia J. Rutherford, Chester A. Alper, Fred S. Rosen, Bernard M. Babior

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Agarose beads to which [35S]cysteine had been attached by a disulfide bond were incubated in serum under conditions which permitted complement fixation via the alternative pathway, then washed and treated with dithiothreitol to release the cysteine. The dithiothreitol eluate contained C3b fragments which had been labeled covalently by the radioactive cysteine. Labeling was postulated to involve the reaction of the amino group of the cysteine with the "labile site," an acylating group which is exposed when C3 is converted to C3b during the operation of the alternative complement-fixing pathway.

Original languageEnglish (US)
Pages (from-to)76-82
Number of pages7
JournalClinical Immunology and Immunopathology
Volume26
Issue number1
DOIs
StatePublished - 1983

Fingerprint

Alternative Complement Pathway
Cysteine
Dithiothreitol
Disulfides
Sepharose
Serum

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

Attachment of [35S]cysteine to the labile site of the third component of complement via the alternative pathway. / Rutherford, Cynthia J.; Alper, Chester A.; Rosen, Fred S.; Babior, Bernard M.

In: Clinical Immunology and Immunopathology, Vol. 26, No. 1, 1983, p. 76-82.

Research output: Contribution to journalArticle

@article{c13fa151a83240c58b002aef2c74d1bc,
title = "Attachment of [35S]cysteine to the labile site of the third component of complement via the alternative pathway",
abstract = "Agarose beads to which [35S]cysteine had been attached by a disulfide bond were incubated in serum under conditions which permitted complement fixation via the alternative pathway, then washed and treated with dithiothreitol to release the cysteine. The dithiothreitol eluate contained C3b fragments which had been labeled covalently by the radioactive cysteine. Labeling was postulated to involve the reaction of the amino group of the cysteine with the {"}labile site,{"} an acylating group which is exposed when C3 is converted to C3b during the operation of the alternative complement-fixing pathway.",
author = "Rutherford, {Cynthia J.} and Alper, {Chester A.} and Rosen, {Fred S.} and Babior, {Bernard M.}",
year = "1983",
doi = "10.1016/0090-1229(83)90175-7",
language = "English (US)",
volume = "26",
pages = "76--82",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Attachment of [35S]cysteine to the labile site of the third component of complement via the alternative pathway

AU - Rutherford, Cynthia J.

AU - Alper, Chester A.

AU - Rosen, Fred S.

AU - Babior, Bernard M.

PY - 1983

Y1 - 1983

N2 - Agarose beads to which [35S]cysteine had been attached by a disulfide bond were incubated in serum under conditions which permitted complement fixation via the alternative pathway, then washed and treated with dithiothreitol to release the cysteine. The dithiothreitol eluate contained C3b fragments which had been labeled covalently by the radioactive cysteine. Labeling was postulated to involve the reaction of the amino group of the cysteine with the "labile site," an acylating group which is exposed when C3 is converted to C3b during the operation of the alternative complement-fixing pathway.

AB - Agarose beads to which [35S]cysteine had been attached by a disulfide bond were incubated in serum under conditions which permitted complement fixation via the alternative pathway, then washed and treated with dithiothreitol to release the cysteine. The dithiothreitol eluate contained C3b fragments which had been labeled covalently by the radioactive cysteine. Labeling was postulated to involve the reaction of the amino group of the cysteine with the "labile site," an acylating group which is exposed when C3 is converted to C3b during the operation of the alternative complement-fixing pathway.

UR - http://www.scopus.com/inward/record.url?scp=0020647493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020647493&partnerID=8YFLogxK

U2 - 10.1016/0090-1229(83)90175-7

DO - 10.1016/0090-1229(83)90175-7

M3 - Article

VL - 26

SP - 76

EP - 82

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -